Drug Profile

PF 06842874

Alternative Names: PF-06842874

Latest Information Update: 07 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Class Small molecules
Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pulmonary arterial hypertension
New Molecular Entity Yes

02 Nov 2021 Discontinued - Phase-I for Pulmonary arterial hypertension (In volunteers) in USA (PO,Controlled release) (Pfizer's pipeline, November 2021)
02 Nov 2021 Discontinued - Phase-I for Pulmonary arterial hypertension (In volunteers) in USA (PO,Immediate release) (Pfizer's pipeline, November 2021)
28 Jul 2021 PF 06842874 receives Orphan Drug status for Pulmonary arterial hypertension in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com